Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
asthma
Biotech
Sanofi-backed Windward breezes toward $204M IPO
Windward Bio is sailing toward the Nasdaq with the aim of raising over $200 million in proceeds to fund two respiratory drugs licensed from China.
James Waldron
Nov 9, 2026 9:05am
Lycia leaps onto Nasdaq with $318M IPO as Windward eyes debut
Oct 26, 2026 10:00am
Connect not dismayed by Dupixent rival's ph. 2 asthma failure
Sep 15, 2026 9:55am
Windward breezes toward phase 3 with $165M for TSLP ambitions
May 4, 2026 10:31am
AstraZeneca FLAP inhibitor flunks ph. 2 asthma trial
Apr 29, 2026 8:38am
AstraZeneca’s faith in IL-33 blocker pays off with new ph. 3 win
Apr 20, 2026 7:22am